Charles Makin

Charles Makin is the Head of Integrated Evidence and RWE at Boehringer Ingelheim since 2023, overseeing integrated evidence strategy across the drug development lifecycle. Prior to this, Charles held dual roles at Biogen from 2018 to 2023, leading teams focused on RWE, HEOR, HTA, and market access while contributing to governance councils. Charles also served as Executive Director and Head of Health Outcomes Research and Senior Director of Global RWE Strategy at Biogen, where responsibilities included the development and execution of evidence generation frameworks. Previous positions include General Manager and Vice President at ICON plc and various roles at IQVIA, UnitedHealth Group, Elevance Health, and Humana, demonstrating extensive expertise in health economics and outcomes research. Charles holds multiple degrees, including an MBA and MS in Pharmacy Administration from Purdue University and Goldey-Beacom College.